China Merchants Innovation Growth Hybrid Securities Investment Fund (hereinafter referred to as China Merchants Innovation Growth Hybrid C, code 009361) announced its latest net value on September 27, up 3.41 percent.

China Merchants Innovation Growth Hybrid C was established on June 17, 2020, with a performance benchmark of CSI 300 Index yield x 60% + Hang Seng Index yield (converted using valuation exchange rates) x 10% + CSI Total Bond Index yield x 30%. The fund has earned -29.35 per cent since its inception, -14.66 per cent this year, 10.60 per cent in January, -7.47 per cent in one year and -30.37 per cent in three years. For nearly a year, the fund ranked 3241/6716 in its class.

The fund manager is Li Jiacun. Li Jiaxun has managed (or intends to manage) the fund since May 6, 2020, with a gain of -29.35 per cent during his tenure.

According to the latest periodic report, the top ten stocks of the fund are as follows:

pharmaceutical

Stock Code	Stock Name	Position Percentage		open market value (yuan)
	300253	Weining health	5.88	3300047	35.7065 million
300705		5.53	1271079	33.5946 million
000963	Huadong Medicine	5.22	730850	31.697 million
600079	Renfu Medicine	5.05	1137352	30.6403 million
688658	Yuekang Pharmaceutical	4.65	1357880	28.2575 million
002317	All Life Pharmaceuticals	4.56	1628994	27.6766 million
688114	Huada Zhizao	4.25%	298157	25.8085 million
688076	Nuotai Biology	3.91%	667281	23.7419 million
	688276		3.55	344660	21.5757 million
300896		3.47	%		47400	21.0906 million

Now I will give you a red envelope of 60 yuan, direct cash withdrawal is not routine. Please participate in the activity to receive it.